Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Fort Wayne Medical Oncology and Hematology Inc

Neither a doctor nor a teaching hospital

Research payments

$2,101,211

788 payments

Through program year 2025, Fort Wayne Medical Oncology and Hematology Inc is reported as receiving $2,101,211 in research payments, across 788 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,084,951 497
2024 Research $415,089 231
2023 Research $266,894 23
2022 Research $22,550 3
2021 Research $112,806 14
2020 Research $105,435 9
2019 Research $93,486 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $761,403 689 payments
  2. Genentech, Inc. $689,980 66 payments
  3. PharmaEssentia USA Corporation $325,886 8 payments
  4. Pfizer Inc. $316,442 24 payments
  5. Helsinn Healthcare SA $7,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab $630,603 595 payments
  2. Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma $429,478 39 payments
  3. A22-301 $325,886 8 payments
  4. A Phase 1 Study of Sgnb6a in Advanced Solid Tumors $263,131 12 payments
  5. Dlbcl Salvage SD PD Or Consolidation PR Post Induction Therapy 1L Dlbcl in Elderly Frail $208,756 19 payments
  6. M15-656 $84,226 8 payments
  7. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab $46,574 86 payments
  8. Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy $44,944 3 payments
  9. A Phase 1B 12Week Openlabel Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics Following Repeated Subcutaneous Administrations of Pf06946860 in Patients With Cancer and Cachexia $34,878 9 payments
  10. A 6Week Randomized Doubleblind Sponsoropen Study to Assess the Effect of Repeated Subcutaneous Administration of Pf06946860 on Appetite in Participants With Advanced Cancer and Anorexia Followed By An 18Week Openlabel Treatment Period $18,432 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record